Vafseo Tablet, Film Coated
FDA Label NDC 59922-641

36 label sections · Submitted to the FDA by Akebia Therapeutics, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Akebia Therapeutics, Inc. for the product Vafseo (NDC 59922-641). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, 1 indications and usage, 2.1 pre-treatment and on-treatment evaluations of anemia, iron stores, and liver tests, 2.2 important dosing information, 2.3 recommended starting dose of vafseo, 2.4 monitoring response to therapy and dose adjustment, 2.5 dosage adjustments due to drug interactions, 3 dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.